Cover Image
QR Code

TLR9 agonist may improve melanoma Tx response.

Published in:Dermatology Times Vol. 39; no. 10; pp. 59 - 60
Main Author: LEVITAN, DAVE
Format: Journal Article
Published: MJH Life Sciences Oct2018
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=132756271&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 132756271
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01966197
        DTI
      jtl: Dermatology Times
      issn: 01966197
      maglogo: N
    pubinfo:
      dt: Oct2018
      vid: 39
      iid: 10
      pid: 54670
      pub: MJH Life Sciences
      place: Cranbury, New Jersey
    artinfo:
      ui:
        132756271
        132756271
      ppf: 59
      ppct: 1
      formats:
      tig:
        atl: TLR9 agonist may improve melanoma Tx response.
      aug:
        au: LEVITAN, DAVE
      sug:
        subj:
          Melanoma Drug Therapy
          Toll-Like Receptors Antagonists and Inhibitors
          Toll-Like Receptors Therapeutic Use
          Treatment Outcomes
          Antigens, Surface Therapeutic Use
          Immunotherapy
          Disease Progression
          Melanoma Prognosis
          Patient Attitudes
          Adverse Drug Event
      pubtype: Trade Publication
      doctype: Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N